Standout Papers
Citation Impact
Citing Papers
Standardized Low–Molecular-Weight Heparin Bridging Regimen in Outpatients on Oral Anticoagulants Undergoing Invasive Procedure or Surgery
2009
Cost-Effectiveness of Dabigatran for Stroke Prophylaxis in Atrial Fibrillation
2011
Effect of Clopidogrel Added to Aspirin in Patients with Atrial Fibrillation
2009 Standout
Guidelines for the Management of Spontaneous Intracerebral Hemorrhage
2015 Standout
Apixaban in Comparison With Warfarin in Patients With Atrial Fibrillation and Valvular Heart Disease
2015
Efficacy and Safety of the Novel Oral Anticoagulants in Atrial Fibrillation
2012
Guidelines for the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack
2014 Standout
Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update 2014
2015 Standout
Telmisartan, Ramipril, or Both in Patients at High Risk for Vascular Events
2008 Standout
Reversal of Rivaroxaban and Dabigatran by Prothrombin Complex Concentrate
2011
Meta-Analysis Comparing the Effectiveness and Adverse Outcomes of Antifibrinolytic Agents in Cardiac Surgery
2007
A Model for Perioperative Outpatient Management of Anticoagulation in High-Risk Patients: An Evaluation of Effectiveness and Safety
2001
Guidelines for the Primary Prevention of Stroke A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association The American Academy of Neurology affirms the value of this guideline as an educational tool for neurologists.
2011
Clinical outcomes with unfractionated heparin or low‐molecular‐weight heparin as bridging therapy in patients on long‐term oral anticoagulants: the REGIMEN registry
2006
Primary thromboprophylaxis for cancer patients with central venous catheters – a reappraisal of the evidence
2006
Effect of heart rate control on coagulation status in patients of rheumatic mitral stenosis with atrial fibrillation – A pilot study
2015
Double-blind randomised trial of very-low-dose warfarin for prevention of thromboembolism in stage IV breast cancer
1994
Anticoagulant Use in Patients with Chronic Renal Impairment
2005
Bleeding complications of oral anticoagulant treatment: an inception-cohort, prospective collaborative study (ISCOAT)
1996
The Effectiveness of Warfarin Dosing from a Nomogram Compared with House Staff Dosing
2007
Over-the-counter vitamin K1-containing multivitamin supplements disrupt warfarin anticoagulation in vitamin K1-depleted patients
2004
Dental extractions in patients on warfarin: is alteration of anticoagulant regime necessary?
1998
Antithrombotic Therapy for Venous Thromboembolic Disease
2008 Standout
Coadministration of Dabigatran Etexilate and Atorvastatin
2009
Pharmacokinetics and Pharmacodynamics of Dabigatran Etexilate, an Oral Direct Thrombin Inhibitor, Are Not Affected by Moderate Hepatic Impairment
2008
Prevention of bleeding after cardiopulmonary bypass with high-dose tranexamic acid
1995
Antithrombotic management of patients with prosthetic heart valves: current evidence and future trends
2009
Subcutaneous Enoxaparin Once or Twice Daily Compared with Intravenous Unfractionated Heparin for Treatment of Venous Thromboembolic Disease
2001
Reversal of the International Normalized Ratio with recombinant activated factor VII in central nervous system bleeding during warfarin thromboprophylaxis
2003
A Prospective, Randomized Pilot Trial of Model-Based Warfarin Dose Initiation using CYP2C9 Genotype and Clinical Data
2005
Periprocedural Anticoagulation Management of Patients With Nonvalvular Atrial Fibrillation
2008
Proton relaxation enhancement by means of serum albumin and poly-l-lysine labeled with DTPA-Gd3+: Relaxivities as a function of molecular weight and conjugation efficiency
1992
Aprotinin versus desmopressin for patients undergoing operations with cardiopulmonary bypass
1995
The Dose-Response Relationship of Tranexamic Acid
1995
New Oral Anticoagulants Increase Risk for Gastrointestinal Bleeding: A Systematic Review and Meta-analysis
2013
Antifibrinolytic drugs and perioperative hemostasis
1997
Enoxaparin followed by once-weekly idrabiotaparinux versus enoxaparin plus warfarin for patients with acute symptomatic pulmonary embolism: a randomised, double-blind, double-dummy, non-inferiority trial
2011
The Effect of Prophylactic ε-Aminocaproic Acid on Bleeding, Transfusions, Platelet Function, and Fibrinolysis during Coronary Artery Bypass Grafting
1999
Aspirin plus warfarin compared to aspirin alone after acute coronary syndromes: an updated and comprehensive meta-analysis of 25 307 patients
2005
Anticoagulation for patients with cancer and central venous catheters
2011
Urgent reversal of warfarin with prothrombin complex concentrate
2006
Safety profile of tinzaparin versus subcutaneous unfractionated heparin in elderly patients with impaired renal function treated for acute deep vein thrombosis: The Innohep® in Renal Insufficiency Study (IRIS)
2011
Bleeding with anticoagulation therapy – Who is at risk, and how best to identify such patients
2009
Effect of Food, an Antacid, and the H2 Antagonist Ranitidine on the Absorption of BAY 59–7939 (Rivaroxaban), an Oral, Direct Factor Xa Inhibitor, in Healthy Subjects
2006
Anticoagulants and Their Reversal
2006
Safety of continuing warfarin therapy during cataract surgery: A systematic review and meta-analysis
2009
Pharmacodynamic resistance to warfarin associated with a Val66Met substitution in vitamin K epoxide reductase complex subunit 1
2004
Assessment of laboratory assays to measure rivaroxaban – an oral, direct factor Xa inhibitor
2010
Effect of a Centralized Clinical Pharmacy Anticoagulation Service on the Outcomes of Anticoagulation Therapy
2005
Evidence-Based Management of Anticoagulant Therapy
2012
How Safely and for How Long Can Warfarin Therapy Be Withheld in Prosthetic Heart Valve Patients Hospitalized With a Major Hemorrhage?
2001
High-dose aprotinin in cardiac surgery: Three years' experience in 1,784 patients
1992
Warfarin Maintenance Dosing Patterns in Clinical Practice
2005
Avoidance of Bleeding During Surgery in Patients Receiving Anticoagulant and/or Antiplatelet Therapy
2004
Perioperative Bridging Anticoagulation in Patients with Atrial Fibrillation
2015
Controversies in Timing of the First Dose of Anticoagulant Prophylaxis Against Venous Thromboembolism After Major Orthopedic Surgery
2003
Drugs to Minimize Perioperative Blood Loss in Cardiac Surgery
1997
Rationale and design of ACTIVE: The atrial fibrillation clopidogrel trial with irbesartan for prevention of vascular events
2006
Antithrombotic therapy in patients treated with oral anticoagulation undergoing coronary artery stenting. An expert consensus document with focus on atrial fibrillation
2008
Mutations in VKORC1 cause warfarin resistance and multiple coagulation factor deficiency type 2
2004 StandoutNature
Prevention of VTE in Orthopedic Surgery Patients
2012 Standout
Costs and Clinical Outcomes Associated With Low-Molecular-Weight Heparin vs Unfractionated Heparin for Perioperative Bridging in Patients Receiving Long-term Oral Anticoagulant Therapy
2004
The international normalized ratio calibrated for cirrhosis (INRliver) normalizes prothrombin time results for model for end‐stage liver disease calculation†
2007
ERS/ESTS clinical guidelines on fitness for radical therapy in lung cancer patients (surgery and chemo-radiotherapy)
2009 Standout
Warfarin reversal
2004
New Antithrombotic Drugs
2008
2008 Focused Update Incorporated Into the ACC/AHA 2006 Guidelines for the Management of Patients With Valvular Heart Disease
2008
Drug-Induced Liver Injury in Humans: The Case of Ximelagatran
2009
Heparin-Induced Thrombocytopenia: Recognition, Treatment, and Prevention
2004
Safety, pharmacodynamics, and pharmacokinetics of BAY 59-7939—an oral, direct Factor Xa inhibitor—after multiple dosing in healthy male subjects
2005
Perioperative Management of Antithrombotic Therapy
2012 Standout
Association Between CYP2C9 Genetic Variants and Anticoagulation-Related Outcomes During Warfarin Therapy
2002 Standout
Oral Anticoagulant Therapy
2012 Standout
Rivaroxaban versus Enoxaparin for Thromboprophylaxis after Total Knee Arthroplasty
2008
Reversal of excessive oral anticoagulation with a low oral dose of vitamin K1 compared with acenocoumarine discontinuation. A prospective, randomized, open study
2001
Extended outpatient therapy with low molecular weight heparin for the treatment of recurrent venous thromboembolism despite warfarin therapy
2001
Effect of low-dose aprotinin on coagulation and fibrinolysis in cardiopulmonary bypass
1993
Daily vitamin K supplementation improves anticoagulant stability
2007
Antithrombotic Therapy for VTE Disease
2016 Standout
Emergency Neurological Life Support: Intracerebral Hemorrhage
2012
Perioperative management of patients receiving vitamin K antagonists
2006
Can oral vitamin K before elective surgery substitute for preoperative heparin bridging in patients on vitamin K antagonists?
2009
A Meta-Analysis of Randomized Controlled Trials of the Risk of Bleeding With Apixaban Versus Vitamin K Antagonists
2014
Combined genetic profiles of components and regulators of the vitamin K-dependent γ-carboxylation system affect individual sensitivity to warfarin
2006
Comparison of a daily fixed 2.5-mg warfarin dose with a 5-mg, international normalized ratio adjusted, warfarin dose initially following heart valve replacement
2001
The incidence of anaphylaxis following intravenous phytonadione (vitamin K1): a 5-year retrospective review
2002
Risk of Upper Gastrointestinal Hemorrhage in Warfarin Users Treated With Nonselective NSAIDs or COX-2 Inhibitors
2005
Use of enoxaparin for the chronically anticoagulated patient before and after procedures
1999
Improved endothelial cell attachment on ePTFE vascular grafts pretreated with synthetic RGD-containing peptides
1996
A Double-Blind, Placebo-Controlled Trial of Epsilon-Aminocaproic Acid for Reducing Blood Loss in Coronary Artery Bypass Grafting Surgery
2005
Apixaban or Enoxaparin for Thromboprophylaxis after Knee Replacement
2009
The interval between prothrombin time tests and the quality of oral anticoagulants treatment in patients with chronic atrial fibrillation
2006
Risk of Thromboembolism With Short-term Interruption of Warfarin Therapy
2008
Rivaroxaban
2011
Chiral phase analysis of warfarin enantiomers in patient plasma in relation to CYP2C9 genotype
1998
Prevention and treatment of bleeding complications in patients receiving vitamin K antagonists, part 2: Treatment
2009
Pharmacokinetics and Pharmacodynamics of the Direct Oral Thrombin Inhibitor Dabigatran in Healthy Elderly Subjects
2008
Prognostic Value of ECG Among Patients with Acute Pulmonary Embolism and Normal Blood Pressure
2009
Emergency Hospitalizations for Adverse Drug Events in Older Americans
2011 Standout
Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomised double-blind trial
2010
The development and application of a surface plasmon resonance-based inhibition immunoassay for the determination of warfarin in plasma ultrafiltrate
2004
Population Pharmacokinetics and Pharmacodynamics of Rivaroxaban – an Oral, Direct Factor Xa Inhibitor – in Patients Undergoing Major Orthopaedic Surgery
2008
Perioperative anticoagulation management in patients who are receiving oral anticoagulant therapy: a practical guide for clinicians
2002
Perioperative Bridging Therapy With Unfractionated Heparin or Low-Molecular-Weight Heparin in Patients With Mechanical Prosthetic Heart Valves on Long-Term Oral Anticoagulants (from the REGIMEN Registry)
2008
Comparison of efficacy, safety, and cost of low-molecular-weight heparin with continuous-infusion unfractionated heparin for initiation of anticoagulation after mechanical prosthetic valve implantation
2004
Prospective dosing of warfarin based on cytochrome P-450 2C9 genotype
2005
Experience with enoxaparin in patients with mechanical heart valves who must withhold acenocumarol
2003
Hemostatic Drugs
1998
Therapy of venous thromboembolism in patients with brain metastases
1994
COMPARISON OF A NOMOGRAMAND PHYSICIAN-ADJUSTED DOSAGE OF WARFARIN FOR PROPHYLAXIS AGAINST DEEP-VEIN THROMBOSIS AFTER ARTHROPLASTY
2002
An evidence‐based review and guidelines for patient self‐testing and management of oral anticoagulation
2005
Effect of tranexamic acid on blood loss reduction after cardiopulmonary bypass
2001
Does the clinical presentation and extent of venous thrombosis predict likelihood and type of recurrence? A patient‐level meta‐analysis
2010
Reduction of bleeding after heart operations through the prophylactic use of epsilon-aminocaproic acid
1996
New Antithrombotic Drugs
2009
European Concerted Action on Anticoagulation (ECAA): multicentre international sensitivity index calibration of two types of point‐of‐care prothrombin time monitor systems
2002
Can Selected Patients With Newly Diagnosed Pulmonary Embolism Be Safely Treated Without Hospitalization? A Systematic Review
2012
Guidelines for the Primary Prevention of Stroke
2010
Evaluation of Warfarin Initiation Regimens in Elderly Inpatients
2000
Oral anticoagulation in patients with cancer who have no therapeutic or prophylactic indication for anticoagulation
2010
Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation
2011 Standout
The Risk of Hemorrhage Among Patients With Warfarin-Associated Coagulopathy
2006
Prevention of VTE in Nonsurgical Patients
2012 Standout
Tranexamic Acid Reduces Blood Loss, Transfusion Requirements, and Coagulation Factor Use in Primary Orthotopic Liver Transplantation
1996
Effect of VKORC1 Haplotypes on Transcriptional Regulation and Warfarin Dose
2005
Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials
2013 Standout
The cardiac toxicity of anabolic steroids
1998
Twelve‐month outcomes and predictors of very stable INR control in prevalent warfarin users
2010
Warfarin dosing and cytochrome P450 2C9 polymorphisms
2004
Paracetamol (acetaminophen) warfarin interaction: NAPQI, the toxic metabolite of paracetamol, is an inhibitor of enzymes in the vitamin K cycle
2004
Prospective study of supplemental vitamin K therapy in patients on oral anticoagulants with unstable international normalized ratios
2007
Self-monitoring of oral anticoagulation: a systematic review and meta-analysis
2006
Tranexamic acid and early saphenous vein graft patency in conventional coronary artery bypass graft surgery: A prospective randomized controlled clinical trial
2005
Risks factors for highly unstable response to oral anticoagulation: a case‐control study
2005
Self-Management of Oral Anticoagulant Therapy: A Review
2004
Falsely Elevated International Normalized Ratio Values in Patients Undergoing Anticoagulation Therapy
2007
Optimal Oral Anticoagulant Therapy in Patients with Mechanical Heart Valves
1995
Multicentre randomised study of computerised anticoagulant dosage
1998
Increase in International Normalized Ratio After Smoking Cessation in a Patient Receiving Warfarin
2005
Dose-escalation study of rivaroxaban (BAY 59-7939) – an oral, direct Factor Xa inhibitor – for the prevention of venous thromboembolism in patients undergoing total hip replacement
2007
Novel Oral Anticoagulants in Atrial Fibrillation: A Meta‐analysis of Large, Randomized, Controlled Trials vs Warfarin
2013
Pharmacological strategies to decrease excessive blood loss in cardiac surgery: a meta-analysis of clinically relevant endpoints
1999
Low-molecular-weight heparin as bridging therapy during interruption of oral anticoagulation in patients undergoing colonoscopy or gastroscopy
2007
Pharmacokinetic Profile of the Oral Direct Thrombin Inhibitor Dabigatran Etexilate in Healthy Volunteers and Patients Undergoing Total Hip Replacement
2005
Prothrombin complex concentrate (Beriplex® P/N) for emergency anticoagulation reversal: a prospective multinational clinical trial
2008
Dabigatran versus Warfarin in the Treatment of Acute Venous Thromboembolism
2009 Standout
Cutaneous Surgery in Patients Receiving Warfarin Therapy
2001
Decreased postoperative drainage with addition of ϵ-aminocaproic acid before cardiopulmonary bypass
1994
Bleeding and antidotes in new oral anticoagulants
2013
Platelet Activation and Atherothrombosis
2007 Standout
Acetaminophen and Other Risk Factors for Excessive Warfarin Anticoagulation
1998
Reliability of international normalised ratios from two point of care test systems: comparison with conventional methods
2003
CYP2C9 Genotype-guided Warfarin Prescribing Enhances the Efficacy and Safety of Anticoagulation: A Prospective Randomized Controlled Study
2007
Warfarin and its interactions with foods, herbs and other dietary supplements
2006
Systematic review of studies of self-management of oral anticoagulation
2004
A Comparison of Observational Studies and Randomized, Controlled Trials
2000 Standout
Antithrombotic and anticoagulant effects of the direct thrombin inhibitor dabigatran, and its oral prodrug, dabigatran etexilate, in a rabbit model of venous thrombosis
2007
The Effects of epsilon-Aminocaproic Acid on Fibrinolysis and Thrombin Generation During Cardiac Surgery
1997
Warfarin Interactions With Substances Listed in Drug Information Compendia and in the FDA-Approved Label for Warfarin Sodium
2009
Safety, pharmacodynamics, and pharmacokinetics of single doses of BAY 59-7939, an oral, direct factor Xa inhibitor
2005
The potential role of new oral anticoagulants in the prevention and treatment of thromboembolism
2010
Interaction of Warfarin With Drugs, Natural Substances, and Foods
2005
Percutaneous closure of the left atrial appendage versus warfarin therapy for prevention of stroke in patients with atrial fibrillation: a randomised non-inferiority trial
2009
Self-Managed Long-Term Low-Molecular-Weight Heparin Therapy: The Balance of Benefits and Harms
2007
Anchor extension: a structure-guided approach to design cyclic peptides targeting enzyme active sites
2021 StandoutNobel
Efficacy and Safety of Dabigatran Etexilate and Warfarin in “Real-World” Patients With Atrial Fibrillation
2013
RGD modified polymers: biomaterials for stimulated cell adhesion and beyond
2003 Standout
Use of Pharmacogenetic and Clinical Factors to Predict the Therapeutic Dose of Warfarin
2008
Clinical characteristics and outcomes with rivaroxaban vs. warfarin in patients with non-valvular atrial fibrillation but underlying native mitral and aortic valve disease participating in the ROCKET AF trial
2014
A Disease Management Protocol for Outpatient Perioperative Bridge Therapy with Enoxaparin in Patients Requiring Temporary Interruption of Long‐Term Oral Anticoagulation
2004
Very low-dose warfarin prophylaxis to prevent thromboembolism in women with metastatic breast cancer receiving chemotherapy: an economic evaluation.
1995
The Metabolism and Disposition of the Oral Direct Thrombin Inhibitor, Dabigatran, in Humans
2007
Safety, pharmacokinetics and pharmacodynamics of single doses of rivaroxaban – an oral, direct factor Xa inhibitor – in elderly Chinese subjects
2009
Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion
2011 Standout
Comparison of an Anticoagulation Clinic With Usual Medical Care
1998
Anticoagulation for patients with cancer and central venous catheters
2011
A modified international normalized ratio as an effective way of prothrombin time standardization in hepatology†
2007
Perioperative Management of Oral Anticoagulation: When and How to Bridge
2006
Population pharmacokinetic-pharmacodynamic analysis of fluindione in patients*
1998
Factors Affecting Quality of Anticoagulation Control Among Patients With Atrial Fibrillation on Warfarin
2013
Reliability of the international normalized ratio for monitoring the induction phase of warfarin: Comparison with the prothrombin time ratio
1996
Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial
2007
Dabigatran versus Warfarin in Patients with Atrial Fibrillation
2009 Standout
Tranexamic Acid Reduces Bleeding After Cardiopulmonary Bypass When Compared to Epsilon Aminocaproic Acid and Placebo
1997
Apixaban versus Enoxaparin for Thromboprophylaxis after Hip Replacement
2010
European Concerted Action on Anticoagulation (ECAA). An assessment of lyophilised plasmas for ISI calibration of CoaguChek and TAS whole blood prothrombin time monitors
2003
Prophylactic Treatment of Postperfusion Bleeding Using EACA
1989
10-Year Follow-up of Intensive Glucose Control in Type 2 Diabetes
2008 Standout
The direct thrombin inhibitor melagatran followed by oral ximelagatran compared with enoxaparin for the prevention of venous thromboembolism after total hip or knee replacement: the EXPRESS study
2003
Malignant Gliomas in Adults
2008 Standout
A Feasibility Study of Continuing Dose-Reduced Warfarin for Invasive Procedures in Patients With High Thromboembolic Risk
2005
New Anticoagulant Agents: Direct Thrombin Inhibitors
2008
Flexibility in Administration of Fondaparinux for Prevention of Symptomatic Venous Thromboembolism in Orthopaedic Surgery
2006
A randomized phase II trial of apixaban for the prevention of thromboembolism in patients with metastatic cancer
2012
Prevention of Venous Thromboembolism
2004 Standout
Evaluation of the novel factor Xa inhibitor edoxaban compared with warfarin in patients with atrial fibrillation: Design and rationale for the Effective aNticoaGulation with factor xA next GEneration in Atrial Fibrillation–Thrombolysis In Myocardial Infarction study 48 (ENGAGE AF–TIMI 48)
2010
Low-Molecular-Weight Heparin versus a Coumarin for the Prevention of Recurrent Venous Thromboembolism in Patients with Cancer
2003 Standout
Risk factors for nonadherence to warfarin: results from the IN‐RANGE study
2008
Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of Rivaroxaban—an Oral, Direct Factor Xa Inhibitor—Are Not Affected by Aspirin
2006
External quality assessment (EQA) for CoaguChek monitors
2010
Heparin-Induced Thrombocytopenia in Patients Treated with Low-Molecular-Weight Heparin or Unfractionated Heparin
1995 Standout
Antithrombotic Therapy in Peripheral Arterial Occlusive Disease
2001
Randomized, Prospective Trial Comparing Bridging Therapy Using Low-Molecular-Weight Heparin With Maintenance of Oral Anticoagulation During Extraction of Teeth
2009
Parenteral anticoagulation in patients with cancer who have no therapeutic or prophylactic indication for anticoagulation
2011
Interindividual variability in sensitivity to warfarin-Nature or nurture?
2001
Prothrombin complex concentrate (Octaplex®) in patients requiring immediate reversal of oral anticoagulation
2007
Comparison of Safety of Subcutaneous Enoxaparin as Outpatient Anticoagulation Bridging Therapy in Patients With a Mechanical Heart Valve Versus Patients With Nonvalvular Atrial Fibrillation
2009
A Randomized Trial of Genotype-Guided Dosing of Acenocoumarol and Phenprocoumon
2013
Bleeding and Thromboembolism During Anticoagulant Therapy:A Population-Based Study in Rochester, Minnesota
1995
Meta-Analysis of Efficacy and Safety of New Oral Anticoagulants (Dabigatran, Rivaroxaban, Apixaban) Versus Warfarin in Patients With Atrial Fibrillation
2012
Implantation of cardiac rhythm devices without interruption of oral anticoagulation compared with perioperative bridging with low–molecular weight heparin
2009
Guidelines for the Use of Retrievable and Convertible Vena Cava Filters: Report from the Society of Interventional Radiology Multidisciplinary Consensus Conference
2006
Adverse effects of methods for minimizing perioperative allogeneic transfusion: A critical review of the literature
1998
Hemostatic Management of Tooth Extractions in Patients on Oral Antithrombotic Therapy
2008
Effect of Study Setting on Anticoagulation Control
2006
Randomized, Controlled Trials, Observational Studies, and the Hierarchy of Research Designs
2000 Standout
Effects of prothrombin complex concentrate and recombinant activated factor VII on vitamin K antagonist induced anticoagulation
2007
Randomized, Placebo‐Controlled Trial of Oral Phytonadione for Excessive Anticoagulation
2000
Ximelagatran vs Low-Molecular-Weight Heparin and Warfarin for the Treatment of Deep Vein Thrombosis
2005
A Comparison Between Six- and Four-Week Intervals in Surveillance of Oral Anticoagulant Treatment
2003
Rivaroxaban versus Enoxaparin for Thromboprophylaxis after Hip Arthroplasty
2008 Standout
Oral, direct Factor Xa inhibition with BAY 59‐7939 for the prevention of venous thromboembolism after total hip replacement
2005
Comparison of Enoxaparin and Warfarin for the Prevention of Venous Thromboembolic Disease After Total Hip Arthroplasty. Evaluation During Hospitalization and Three Months After Discharge*
1999
Andexanet Alfa for the Reversal of Factor Xa Inhibitor Activity
2015
Heparin‐induced thrombocytopenia: mechanism of interaction of the heparin‐dependent antibody with platelets
1989
Management patterns and outcomes of patients with venous thromboembolism in the usual community practice setting
2004
Initiation of warfarin therapy in elderly medical inpatients: A safe and accurate regimen
2005
Prevention and treatment of bleeding complications in patients receiving vitamin K antagonists, Part 1: Prevention
2009
Systematic Overview of Warfarin and Its Drug and Food Interactions
2005 Standout
Role of prothrombin complex concentrates in reversing warfarin anticoagulation: A review of the literature
2007
A comparison of the efficacy and rate of response to oral and intravenous Vitamin K in reversal of over‐anticoagulation with warfarin
2001
Dabigatran Versus Warfarin After Bioprosthesis Valve Replacement for the Management of Atrial Fibrillation Postoperatively: DAWA Pilot Study
2016
Prevention of Venous Thromboembolism
2008 Standout
Comparison of Low-Intensity Warfarin Therapy with Conventional-Intensity Warfarin Therapy for Long-Term Prevention of Recurrent Venous Thromboembolism
2003
Metabolism of warfarin enantiomers in Japanese patients with heart disease having different CYP2C9 and CYP2C19 genotypes*
1998
The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects
2007
Apixaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a subgroup analysis of the ARISTOTLE trial
2012
Antithrombotic Therapy in Neonates and Children
2012
Comparison of ximelagatran, an oral direct thrombin inhibitor, with enoxaparin for the prevention of venous thromboembolism following total hip replacement. A randomized, double-blind study
2003
Improving the quality of anticoagulation of patients with atrial fibrillation in managed care organizations: results of the managing anticoagulation services trial
2002
Ultrasound screening for asymptomatic deep vein thrombosis after major orthopaedic surgery: the VENUS study
2007
Comparative Pharmacokinetics of Vitamin K Antagonists
2005
Regional Anesthesia in the Patient Receiving Antithrombotic or Thrombolytic Therapy
2009 Standout
Comparison of INR stability between self-monitoring and standard laboratory method: Preliminary results of a prospective study in 67 mechanical heart valve patients
2008
Long-term Low-Molecular-Weight Heparin versus Usual Care in Proximal-Vein Thrombosis Patients with Cancer
2006
A prognostic model for predicting the disappearance of left atrial thrombi among candidates for percutaneous transvenous mitral commissurotomy
2002
Recombinant factor VIIa for warfarin-associated intracranial bleeding
2008
The reliability of point‐of‐care prothrombin time testing. A comparison of CoaguChek S® and XS® INR measurements with hospital laboratory monitoring
2008
Antithrombotic Therapy for Venous Thromboembolic Disease
2001 Standout
Efficacy and Safety of Anticoagulant Therapy for the Treatment of Acute Cancer-Associated Thrombosis: A Systematic Review and Meta-Analysis
2014
An Analysis of the Lowest Effective Intensity of Prophylactic Anticoagulation for Patients with Nonrheumatic Atrial Fibrillation
1996
Hemorrhagic Complications of Anticoagulant and Thrombolytic Treatment
2008
Safety, pharmacokinetics and pharmacodynamics of single/multiple doses of the oral, direct Factor Xa inhibitor rivaroxaban in healthy Chinese subjects
2009
Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion
1999
Prediction of the Risk of Bleeding During Anticoagulant Treatment for Venous Thromboembolism
1999
Dabigatran Etexilate: An Oral Direct Thrombin Inhibitor for Prophylaxis and Treatment of Thromboembolic Diseases
2008
Warfarin for atrial fibrillation in community‐based practise
2008
Patients requiring interruption of long‐term oral anticoagulant therapy: the use of fixed sub‐therapeutic doses of low‐molecular‐weight heparin
2009
Influence of CYP2C9 and VKORC1 on warfarin response during initiation of therapy
2009
Influence of dietary vitamin K intake on subtherapeutic oral anticoagulant therapy
2010
Peri-procedural anticoagulation management of mechanical prosthetic heart valve patients
2009
Does heart failure exacerbation increase response to warfarin?A critical review of the literature
2006
Tranexamic acid reduces bleeding and the need for blood transfusion in primary myocardial revascularization
2002
In vitro and in vivo studies of the novel antithrombotic agent BAY 59-7939—an oral, direct Factor Xa inhibitor
2005
Use of Low-Molecular-Weight Heparin During Dental Extractions in a Medicaid Population
2007
Individual time within target range in patients treated with vitamin K antagonists: main determinant of quality of anticoagulation and predictor of clinical outcome. a retrospective study of 2300 consecutive patients with venous thromboembolism
2005
Low-Molecular-Weight Heparin as Bridging Anticoagulation During Interruption of Warfarin
2004
What Is the Evidence for the Off-label Use of Recombinant Factor VIIa (rFVIIa) in the Acute Reversal of Warfarin?
2008
Comparison of Ximelagatran with Warfarin for the Prevention of Venous Thromboembolism after Total Knee Replacement
2003
Interactions between endothelial nitric oxide synthase and sex hormones in vascular protection in mice
2002 StandoutNobel
International Normalized Ratio Self-Management Lowers the Risk of Thromboembolic Events After Prosthetic Heart Valve Replacement
2008
Low‐Dose Vitamin K to Augment Anticoagulation Control
2005
LOWERing the INtensity of oral anticoaGulant Therapy in patients with bileaflet mechanical aortic valve replacement: Results from the “LOWERING-IT” Trial
2010
Accuracy of a Portable International Normalization Ratio Monitor in Outpatients Receiving Long-Term Oral Anticoagulant Therapy
1998
Prevention of venous thromboembolism in orthopedic surgery with vitamin K antagonists: a meta‐analysis
2004
Rates of Initial and Recurrent Thromboembolic Disease Among Patients with Malignancy Versus Those without Malignancy: Risk Analysis Using Medicare Claims Data
1999
Postoperative Low‐Molecular‐Weight Heparin Bridging Is Associated with an Increase in Wound Hematoma Following Surgery for Pacemakers and Implantable Defibrillators
2009
When patients on warfarin need surgery.
2003
Direct oral anticoagulants in the treatment of acute venous thromboembolism: A systematic review and meta-analysis
2014
National Estimates of Emergency Department Visits for Hemorrhage-Related Adverse Events From Clopidogrel Plus Aspirin and From Warfarin
2010
Hemorrhagic Complications of Anticoagulant Treatment
2004
Oral Apixaban for the Treatment of Acute Venous Thromboembolism
2013 Standout
French clinical practice guidelines on the management of patients on vitamin K antagonists in at-risk situations (overdose, risk of bleeding, and active bleeding)
2010
Bed Rest or Ambulation in the Initial Treatment of Patients With Acute Deep Vein Thrombosis or Pulmonary Embolism
2005
Rivaroxaban (BAY 59‐7939) – an oral, direct Factor Xa inhibitor – has no clinically relevant interaction with naproxen
2006
Management of Anticoagulation before and after Elective Surgery
1997
Dabigatran With or Without Concomitant Aspirin Compared With Warfarin Alone in Patients With Nonvalvular Atrial Fibrillation (PETRO Study)
2007
Incidence of thromboembolic complications in patients with mechanical heart valves with a subtherapeutic international normalized ratio
2008
Treatment of coumarin‐associated coagulopathy: a systematic review and proposed treatment algorithms
2006
Prospective evaluation of an index for predicting the risk of major bleeding in outpatients treated with warfarin
1998
Antiplatelet and anticoagulation for patients with prosthetic heart valves
2003
Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease
2012 Standout
Comparison of 5-mg and 10-mg Loading Doses in Initiation of Warfarin Therapy
1997
Regional Anesthesia in the Patient Receiving Antithrombotic or Thrombolytic Therapy
2018
Effect of intraoperative aprotinin administration on postoperative bleeding in patients undergoing cardiopulmonary bypass operation
1991
Cardiac causes of stroke
2000
Time Course of Reversal of Anticoagulant Effect of Warfarin by Intravenous and Subcutaneous Phytonadione
1999
Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial
2006 Standout
Warfarin reversal: consensus guidelines, on behalf of the Australasian Society of Thrombosis and Haemostasis
2004
Tranexamic acid (Cyklokapron) is not necessary to reduce blood loss after coronary artery bypass operations
1993
Crystal Structures of Protein-Bound Cyclic Peptides
2019
A Computer Generated Induction System for Hospitalized Patients Starting on Oral Anticoagulant Therapy
2000
Platelet aggregation in patients with atrial fibrillation taking aspirin or warfarin.
1993
A Multicomponent Intervention To Prevent Major Bleeding Complications in Older Patients Receiving Warfarin
2000
Effect of vitamin K intake on the stability of oral anticoagulant treatment: dose-response relationships in healthy subjects
2004
Outcomes in anticoagulated patients with atrial fibrillation and with mitral or aortic valve disease
2018
Gadolinium(III) Chelates as MRI Contrast Agents: Structure, Dynamics, and Applications
1999 Standout
“Bridging On the River Kwai”: The Perioperative Management of Anticoagulation Therapy
2005
Population pharmacokinetics and pharmacodynamics of once and twice-daily rivaroxaban for the prevention of venous thromboembolism in patients undergoing total hip replacement
2008
Dose-escalation study of the pharmacokinetics and pharmacodynamics of rivaroxaban in healthy elderly subjects
2008
Signaling Recognition Events with Fluorescent Sensors and Switches
1997 Standout
In-vitro profile and ex-vivo anticoagulant activity of the direct thrombin inhibitor dabigatran and its orally active prodrug, dabigatran etexilate
2007
Influence of CYP2C9 and VKORC1 on Warfarin Dose, Anticoagulation Attainment and Maintenance Among European–Americans and African–Americans
2008
Effects of the direct thrombin inhibitor dabigatran and its orally active prodrug, dabigatran etexilate, on thrombus formation and bleeding time in rats
2007
Recommendations for the Management of Intracranial Haemorrhage – Part I: Spontaneous Intracerebral Haemorrhage
2006
Intracerebral Hemorrhage Associated With Oral Anticoagulant Therapy
2005
Interactions between endothelial nitric oxide synthase and sex hormones in vascular protection in mice
2002 StandoutNobel
Evaluation of the Ciba Corning Biotrack 512 coagulation monitor for the control of oral anticoagulation.
1991
Comparison of outcomes among patients randomized to warfarin therapy according to anticoagulant control: results from SPORTIF III and V.
2007
Accuracy of Laboratory and Portable Monitor International Normalized Ratio Determinations
1995
Oral Rivaroxaban for Symptomatic Venous Thromboembolism
2010 Standout
Periprocedural Anticoagulation Management of Patients With Nonvalvular Atrial Fibrillation
2008
Drugs to Minimize Perioperative Blood Loss in Cardiac Surgery
1997
Antiplatelet and anticoagulation for patients with prosthetic heart valves
2013
Low Dose Oral Vitamin K to Reverse Acenocoumarol-induced Coagulopathy: A Randomized Controlled Trial
2002
The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen
2005
Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non-valvular atrial fibrillation (SPORTIF III): randomised controlled trial
2003
Aprotinin therapy for reoperative myocardial revascularization: A placebo-controlled study
1992
Efficacy of apixaban when compared with warfarin in relation to renal function in patients with atrial fibrillation: insights from the ARISTOTLE trial
2012
Timing of Fresh Frozen Plasma Administration and Rapid Correction of Coagulopathy in Warfarin-Related Intracerebral Hemorrhage
2005
Thrombotic and Hemorrhagic Complications in Patients with Mechanical Heart Valve Prosthesis Attending an Anticoagulation Clinic
1993
Anticoagulation for the long-term treatment of venous thromboembolism in patients with cancer
2014
A dose-ranging study evaluating once-daily oral administration of the factor Xa inhibitor rivaroxaban in the treatment of patients with acute symptomatic deep vein thrombosis: the Einstein–DVT Dose-Ranging Study
2008
Periprocedural bridging therapy in patients receiving chronic oral anticoagulation therapy
2006
Guidelines for the Primary Prevention of Stroke
2014 Standout
Guide to anticoagulant therapy. Part 2: Oral anticoagulants. American Heart Association.
1994
Trousseau's syndrome: multiple definitions and multiple mechanisms
2007
Randomized versus historical controls for clinical trials
1982
The effect of low-dose epsilon-aminocaproic acid on patients following coronary artery bypass surgery
1996
Clinical Predictors of Prolonged Delay in Return of the International Normalized Ratio to within the Therapeutic Range after Excessive Anticoagulation with Warfarin
2001
The influence of sequence variations in factor VII, γ-glutamyl carboxylase and vitamin K epoxide reductase complex genes on warfarin dose requirement
2006
Aging and Heparin-Related Bleeding
1996
Risk-Adjusted Percent Time in Therapeutic Range as a Quality Indicator for Outpatient Oral Anticoagulation
2010
Outcomes and predictors of very stable INR control during chronic anticoagulation therapy
2009
Comparative Effectiveness of Warfarin and New Oral Anticoagulants for the Management of Atrial Fibrillation and Venous Thromboembolism
2012
Optimal Timing of Resumption of Warfarin After Intracranial Hemorrhage
2010
Guidelines for the Management of Spontaneous Intracerebral Hemorrhage
2010 Standout
Dalteparin as Periprocedure Anticoagulation for Patients on Warfarin and at High Risk of Thrombosis
2001
Is ε-Aminocaproic Acid as Effective as Aprotinin in Reducing Bleeding With Cardiac Surgery?
1999
Article Commentary: Penny-Wise, Pound-Foolish? Highmark Medicare Services’ Proposal for Anticoagulation Clinic Reimbursement
2010
Subcutaneous Low-Molecular-Weight Heparin vs Warfarin for Prophylaxis of Deep Vein Thrombosis After Hip or Knee Implantation
1997
Improved Oral Anticoagulation After a Dietary Vitamin K–Guided Strategy
2009
The impact of bleeding complications in patients receiving target-specific oral anticoagulants: a systematic review and meta-analysis
2014
Challenges of Establishing New Antithrombotic Therapies in Atrial Fibrillation
2007
Influence of thrombophilia on risk of recurrent venous thromboembolism while on warfarin: results from a randomized trial
2008
ACC/AHA 2006 Guidelines for the Management of Patients With Valvular Heart Disease
2006 Standout
Management of Venous Thromboembolism in Patients With Primary and Metastatic Brain Tumors
2006
Efficacy and safety of combined anticoagulant and antiplatelet therapy versus anticoagulant monotherapy after mechanical heart-valve replacement: A metaanalysis
1995
Long-term Outcomes of Deep-Vein Thrombosis
1995
Reduction in blood loss and blood use after cardiopulmonary bypass with high dose aprotinin (Trasylol)
1989
Prophylactic tranexamic acid decreases bleeding after cardiac operations
1990
A Comparison of Point-of-Care Instruments Designed for Monitoring Oral Anticoagulation with Standard Laboratory Methods
2000
Leukoaraiosis is associated with warfarin-related hemorrhage following ischemic stroke
2002
Low-molecular-weight heparin (nadroparin) and very low doses of warfarin in the prevention of upper extremity thrombosis in cancer patients with indwelling long-term central venous catheters: a pilot randomized trial.
2003
Effects of Non–Vitamin K Antagonist Oral Anticoagulants Versus Warfarin in Patients With Atrial Fibrillation and Valvular Heart Disease: A Systematic Review and Meta‐Analysis
2017
Stroke prevention
2000
A Comparison Between Six- and Four-Week Intervals in Surveillance of Oral Anticoagulant Treatment
2003
Periprocedural bridging therapy with low-molecular-weight heparin in chronically anticoagulated patients with prosthetic mechanical heart valves: experience in 116 patients from the prospective BRAVE registry.
2007
Meta-analysis of trials comparing ximelagatran with low molecular weight heparin for prevention of venous thromboembolism after major orthopaedic surgery
2005
The management of venous thromboembolism in cancer patients
2007
Are Capillary Whole Blood Coagulation Monitors Suitable for the Control of Oral Anticoagulant Treatment by the International Normalized Ratio?
1993
Simple and Safe Method to Prepare Patients With Prosthetic Heart Valves for Surgical Dental Procedures
2000
Systematic Review: d -Dimer to Predict Recurrent Disease after Stopping Anticoagulant Therapy for Unprovoked Venous Thromboembolism
2008
Accuracy and Precision of a Portable Anticoagulation Monitor in a Clinical Setting
1992
Incidence of Recurrent Thromboembolic and Bleeding Complications Among Patients With Venous Thromboembolism in Relation to Both Malignancy and Achieved International Normalized Ratio: A Retrospective Analysis
2000
Warfarin therapy: evolving strategies in anticoagulation.
1999
Ximelagatran versus Warfarin for the Prevention of Venous Thromboembolism after Total Knee Arthroplasty
2002
2020 ACC/AHA Guideline for the Management of Patients With Valvular Heart Disease: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines
2020 Standout
Effect of prophylactic epsilon-aminocaproic acid on blood loss and transfusion requirements in patients undergoing first-time coronary artery bypass grafting
1994
Antithrombotic Therapy in Peripheral Arterial Occlusive Disease
1992
Oral Rivaroxaban for the Treatment of Symptomatic Pulmonary Embolism
2012 Standout
Randomized study of aprotinin and DDAVP to reduce postoperative bleeding after cardiopulmonary bypass surgery.
1994
Patient education and oral anticoagulant therapy.
2002
Pathogenesis and Prophylaxis of Postoperative Thromboembolic Disease in Urological Pelvic Surgery
1995
Perioperative Management of Patients on Oral Anticoagulants: A Decision Analysis
2005
The risk of bleeding with warfarin: A systematic review and performance analysis of clinical prediction rules
2007
Interaction between paracetamol and warfarin in patients: a double-blind, placebo-controlled, randomized study.
2006
Comparing the quality of oral anticoagulant management by anticoagulation clinics and by family physicians: a randomized controlled trial.
2003
Dietary Vitamin and Stability of Oral Anticoagulation: Proposal of a Diet with Constant Vitamin K1 Content
1997
Surface Plasmon Resonance Sensors for Detection of Chemical and Biological Species
2008 Standout
A Multicenter, Double-Blind, Placebo-Controlled Trial of Aprotinin for Reducing Blood Loss and the Requirement for Donor-Blood Transfusion in Patients Undergoing Repeat Coronary Artery Bypass Grafting
1995
Use of enoxaparin, a low-molecular-weight heparin, and unfractionated heparin for the prevention of deep venous thrombosis after elective hip replacement. A clinical trial comparing efficacy and safety. Enoxaparin Clinical Trial Group.
1994
Managing anticoagulant and antiplatelet drugs in patients who are receiving neuraxial anesthesia and epidural analgesia: a practical guide for clinicians
2006
Restarting anticoagulation after intracranial hemorrhage
2011
Optimal Oral Anticoagulant Therapy in Patients with Nonrheumatic Atrial Fibrillation and Recent Cerebral Ischemia
1995
Molecular Dynamics of Ion−Chelate Complexes Attached to Dendrimers
1996 StandoutNobel
Brief Communication: Preoperative Anticoagulant Activity after Bridging Low-Molecular-Weight Heparin for Temporary Interruption of Warfarin
2007
Prolonged Bleeding Times and Bleeding Diathesis Associated With Moxalactam Administration
1983
Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE‐MODEL randomized trial
2007
AREVA: Multicenter Randomized Comparison of Low-Dose Versus Standard-Dose Anticoagulation in Patients With Mechanical Prosthetic Heart Valves
1996
Low Molecular Weight Heparin, Therapy With Dalteparin, and Survival in Advanced Cancer: The Fragmin Advanced Malignancy Outcome Study (FAMOUS)
2004
Heparin-Associated Thrombocytopenia
1984
Monitoring oral anticoagulant treatment with the TAS near-patient test system: comparison with conventional thromboplastins.
1997
Comparison of the effects of aprotinin and tranexamic acid on blood loss and related variables after cardiopulmonary bypass
1994
2017 ACC Expert Consensus Decision Pathway on Management of Bleeding in Patients on Oral Anticoagulants
2017
Metal chelates as probes of biological systems
1984
Increased expression of platelet IgG Fc receptors in immune heparin- induced thrombocytopenia
1993
2008 Focused Update Incorporated Into the ACC/AHA 2006 Guidelines for the Management of Patients With Valvular Heart Disease
2008 Standout
Guidelines for the Prevention of Stroke in Patients With Stroke or Transient Ischemic Attack
2010 Standout
Clinical and Safety Outcomes Associated With Treatment of Acute Venous Thromboembolism
2014
Efficacy and Safety of a 4-Factor Prothrombin Complex Concentrate in Patients on Vitamin K Antagonists Presenting With Major Bleeding
2013
Comparison of Warfarin and Aspirin for Symptomatic Intracranial Arterial Stenosis
2005
Prevention of deep vein thrombosis and pulmonary embolism
2015
Non-vitamin K antagonist oral anticoagulants in atrial fibrillation patients with bioprosthetic valves
2018
Effect of Increased Warfarin Use on Warfarin-Related Cerebral Hemorrhage
2011
Rivaroxaban: A New Oral Factor Xa Inhibitor
2010
Association of Surgical Left Atrial Appendage Occlusion With Subsequent Stroke and Mortality Among Patients Undergoing Cardiac Surgery
2018
A polymorphism in the VKORC1 gene is associated with an interindividual variability in the dose-anticoagulant effect of warfarin
2004
Effect of prophylactic epsilon-aminocaproic acid on blood loss and transfusion requirements in patients undergoing first-time coronary artery bypass grafting. A randomized, prospective, double-blind study.
1994
Withdrawal of Antithrombotic Agents and Its Impact on Ischemic Stroke Occurrence
2011
Minidose Warfarin Prophylaxis for Catheter-Associated Thrombosis in Cancer Patients: Can It Be Safely Associated With Fluorouracil-Based Chemotherapy?
2003
Hemostatic effects of tranexamic acid and desmopressin during cardiac surgery.
1991
Works of Jack Ansell being referenced
Use and Outcomes Associated With Bridging During Anticoagulation Interruptions in Patients With Atrial Fibrillation
2014
Heparin-induced thrombocytopenia and arterialthrombosis: Alternative therapies
1990
Apixaban, an oral direct Factor Xa inhibitor: awaiting the verdict
2008
Pharmacology and Management of the Vitamin K Antagonists
2008 Standout
Treatment of Warfarin-Associated Intracerebral Hemorrhage: Literature Review and Expert Opinion
2007
Clinical outcomes and management associated with major bleeding in patients with atrial fibrillation treated with apixaban or warfarin: insights from the ARISTOTLE trial
2014
Long-Term Anticoagulation Therapy for Atrial Fibrillation in Elderly Patients: Efficacy, Risk, and Current Patterns of Use
1999
Indirect comparison of dabigatran, rivaroxaban, apixaban and edoxaban for the treatment of acute venous thromboembolism
2014
Coagulation abnormalities associated with the use of anabolic steroids
1993
Descriptive analysis of the process and quality of oral anticoagulation management in real-life practice in patients with chronic non-valvular atrial fibrillation: the international study of anticoagulation management (ISAM)
2007
Current Options in the Prevention of Thromboembolic Disease
2004
Barriers to Patient Self‐Testing of Prothrombin Time: National Survey of Anticoagulation Practitioners
2005
Quality Assessment of Anticoagulation Dose Management: Comparative Evaluation of Measures of Time-in-Therapeutic Range
2003
Managing Oral Anticoagulant Therapy
2001
Physician practices regarding contraindications to oral anticoagulation in atrial fibrillation: Findings from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) registry
2014
Aging and the Anticoagulant Response to Warfarin Therapy
1992
Oral Anticoagulants
1998
Consensus Guidelines for Coordinated Outpatient Oral Anticoagulation Therapy Management
1997
An indirect comparison of dabigatran, rivaroxaban and apixaban for atrial fibrillation
2012
The Perioperative Management of Antithrombotic Therapy
2008
Oral Anticoagulants: Mechanism of Action, Clinical Effectiveness, and Optimal Therapeutic Range
2001 Standout
Outpatient management of oral vitamin K antagonist therapy: defining and measuring high-quality management
2007
Future directions of stroke prevention in atrial fibrillation: the potential impact of novel anticoagulants and stroke risk stratification
2010
The efficacy and safety of apixaban, an oral, direct factor Xa inhibitor, as thromboprophylaxis in patients following total knee replacement
2007
Efficacy and safety of apixaban compared with warfarin according to patient risk of stroke and of bleeding in atrial fibrillation: a secondary analysis of a randomised controlled trial
2012
New Targets for Anticoagulation and Future Perspectives
2012
Heparins, Low-Molecular-Weight Heparins, and Pentasaccharides: Use in the Older Patient
2008
The Pharmacology and Management of the Vitamin K Antagonists
2004 Standout
Factor Xa or thrombin: is factor Xa a better target?
2007
Oral anticoagulation with factor Xa and thrombin inhibitors: on the threshold of change
2009
Single-dose ciraparantag safely and completely reverses anticoagulant effects of edoxaban
2016
Ciraparantag safely and completely reverses the anticoagulant effects of low molecular weight heparin
2016
Guidelines for implementation of patient self-testing and patient self-management of oral anticoagulation. International consensus guidelines prepared by International Self-Monitoring Association for Oral Anticoagulation
2004
Apixaban for Reduction In Stroke and Other ThromboemboLic Events in Atrial Fibrillation (ARISTOTLE) trial: Design and rationale
2010
Guidance on the emergent reversal of oral thrombin and factor Xa inhibitors
2012
THE EXPRESS STUDY: PRELIMINARY RESULTS
2003
Evaluation of the viability of In-111-labeled DTPA coupled to fibrinogen.
1982
Precoating expanded polytetrafluoroethylene grafts alters production of endothelial cell[mdash ]derived thrombomodulators
1992
Patient Self-Management of Oral Anticoagulation Guided by Capillary (Fingerstick) Whole Blood Prothrombin Times
1989
Precoating expanded polytetrafluoroethylene grafts alters production of endothelial cell—derived thrombomodulators
1992
Delivery of Optimized Anticoagulant Therapy: Consensus Statement from the Anticoagulation Forum
2008
New anticoagulants and their potential impact on the treatment of thromboembolic disease.
2004
Does desmopressin acetate prophylaxis reduce blood loss after valvular heart operations? A randomized, double-blind study.
1992
Safety and efficacy of long-term oral anticoagulation in cancer patients
1987
Management of thrombosis in the cancer patient.
2004
Vitamin K for reversal of excessive vitamin K antagonist anticoagulation: a systematic review and meta-analysis
2019
American Heart Association/American College of Cardiology Foundation Guide to Warfarin Therapy
2003
Cost Effectiveness of Monitoring Warfarin Therapy Using Standard Versus Capillary Prothrombin Times
1989
Clinical Trial of a New Bleeding-time Device
1978
Imprecision of Prothrombin Time Monitoring of Oral Anticoagulation: A Survey of Hospital Laboratories
1992
Heparin‐induced thrombocytopenia and recurrent thromboembolism
1980
American Heart Association/American College of Cardiology Foundation guide to warfarin therapy11The American Heart Association makes every effort to avoid any actual or potential conflicts of interest that may arise as a result of an outside relationship or a personal, professional, or business interest of a member of the writing panel. Specifically, all members of the writing group are required to complete and submit a Disclosure Questionnaire showing all such relationships that might be perceived as real or potential conflicts of interest.This statement has been co-published in the April 1, 2003, issue of Circulation.This statement was approved by the American Heart Association Science Advisory and Coordinating Committee in October 2002 and by the American College of Cardiology Board of Trustees in February 2003. A single reprint is available by calling 800-242-8721 (US only) or writing the American Heart Association, Public Information, 7272 Greenville Ave, Dallas, TX 75231-4596. Ask for reprint No. 71-0254. To purchase additional reprints: up to 999 copies, call 800-611-6083 (US only) or fax 413-665-2671; 1000 or more copies, call 410-528-4426, fax 410-528-4264, or e-mail klbradle@lww.com. To make photocopies for personal or educational use, call the Copyright Clearance Center, 978-750-8400.
2003
Advances in Therapy and the Management of Antithrombotic Drugs for Venous Thromboembolism
2000
Treatment of Warfarin-Associated Intracerebral Hemorrhage: Literature Review and Expert Opinion
2007
Long-term patient self-management of oral anticoagulation
1995
Anticoagulation Management as a Risk Factor for Adverse Events: Grounds for Improvement
1998
Deep vein thrombosis (DVT) and pulmonary embolism (PE): Awareness and prophylaxis practices reported by patients with cancer.
2011
Heparin Induced Thrombocytopenia: a Prospective Study
1980
Does desmopressin acetate prophylaxis reduce blood loss after valvular heart operations?
1992
Long-term Patient Self-management of Oral Anticoagulation
1995
Feasibility and patients' acceptance of Home Automated Telemanagement of oral anticoagulation therapy.
2003
Management and clinical outcomes in patients treated with apixaban vs warfarin undergoing procedures
2014
Advances in Therapy and the Management of Antithrombotic Drugs for Venous Thromboembolism
2000
College of American Pathologists Conference XXXI on laboratory monitoring of anticoagulant therapy: laboratory monitoring of oral anticoagulant therapy.
1998
Direct thrombin inhibitors
2011
Oral Anticoagulant Therapy—50 Years Later
1993
The role of epsilon-aminocaproic acid in reducing bleeding after cardiac operation: A double-blind randomized study
1988
Control of Bleeding Varices by Vasopressin
1977
A Phase II Randomized, Double-Blind, Eight-Arm, Parallel-Group, Dose-Response Study of Apixaban, a New Oral Factor Xa Inhibitor for the Prevention of Deep Vein Thrombosis in Knee Replacement Surgery - On Behalf of the Apixaban Investigators.
2006
Evolving models of warfarin management: Anticoagulation clinics, patient self-monitoring, and patient self-management
1996